Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 636 News
1 - 10of about 636 News
August 28, 2021
Not intended for U.S. and UK Media – Data from Phase III study FIGARO-DKD and from FIDELITY, a prespecified meta-analysis of FIGARO-DKD and FIDELIO-DKD, presented at ESC Congress 2021
New Data on Finerenone for the protection of patients with chronic kidney disease and type 2 diabetes from cardiovascular events and kidney disease progression
READ MORE
August 17, 2021
Not intended for U.S. and UK Media – ESC Congress 2021 – The Digital Experience:
Bayer to present data from cardiovascular portfolio, including late breaking data from Phase III FIGARO-DKD (finerenone) and various Xarelto™ studies
READ MORE
August 16, 2021
Bayer announces filing of petition to U.S. Supreme Court for review of Hardeman decision
READ MORE
August 05, 2021
Second quarter of 2021
Bayer: Strong growth, guidance upgrade
READ MORE
August 05, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
READ MORE
August 03, 2021
Not intended for U.S. and UK Media
Bayer’s investigational P2X3 antagonist meets primary efficacy endpoint and shows favorable safety and tolerability profile
READ MORE
July 29, 2021
Bayer Provides Update on Path to Closure of Roundup™ Litigation
READ MORE
July 21, 2021
Not intended for U.S. and UK Media
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
READ MORE
July 09, 2021
Not intended for U.S. and UK Media
U.S. FDA approves finerenone for the treatment of patients with chronic kidney disease associated with type 2 diabetes
READ MORE
June 23, 2021
Not intended for U.S. and UK Media
Vericiguat approved in Japan to treat patients with chronic heart failure
READ MORE
1 - 10of about 636 News
1 - 10of about 636 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases

read more